The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hospira's revenues will expand 3.0% and EPS will increase 5.9%.
The average estimate for revenue is $1.04 billion. On the bottom line, the average EPS estimate is $0.54.
Last quarter, Hospira logged revenue of $994.0 million. GAAP reported sales were 1.8% higher than the prior-year quarter's $976.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.47. GAAP EPS were $0.01 for Q3 compared to -$0.54 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 22.0%, 930 basis points worse than the prior-year quarter. Operating margin was -0.3%, 920 basis points worse than the prior-year quarter. Net margin was 0.1%, 920 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $4.03 billion. The average EPS estimate is $2.00.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 128 members out of 154 rating the stock outperform, and 26 members rating it underperform. Among 46 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Hospira a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $35.50.
- Add Hospira to My Watchlist.